Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 1.00 |
| ▸ | MMP13 | P45452 | 5/20 | 1.00 |
| ▸ | MMP9 | P14780 | 4/20 | 0.67 |
| ▸ | MMP8 | P22894 | 4/20 | 0.67 |
| ▸ | MMP12 | P39900 | 4/20 | 0.67 |
| ▸ | MMP3 | P08254 | 3/20 | 0.67 |
| ▸ | MMP14 | P50281 | 3/20 | 0.67 |
| ▸ | MMP16 | P51512 | 3/20 | 0.67 |
| ▸ | PGR | P06401 | 9/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898987 | 0.86 | MMP2 (0.76) | MMP2MMP13MMP9MMP8MMP12 | |
| SCHEMBL12167785 | 0.81 | MMP2 (0.67) | MMP2MMP13PGRMCL1MEN1 | |
| SCHEMBL5898975 | 0.76 | MMP2 (0.64) | MMP2MMP13MMP9MMP8MMP12 | |
| SCHEMBL5187712 | 0.75 | BCAT2 (0.69) | MMP2MMP13MEN1LMNAALOX12 | |
| SCHEMBL15482267 | 0.75 | MMP2 (0.60) | MMP2MMP13MEN1LMNAKMT2A | |
| SCHEMBL15480532 | 0.74 | MMP2 (0.59) | MMP2MMP13MEN1KMT2A | |
| SCHEMBL2905661 | 0.73 | MMP2 (0.68) | MMP2MMP13MMP9MMP8MCL1 | |
| SCHEMBL18392408 | 0.72 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL29539828 | 0.72 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL5188954 | 0.71 | SMN1; SMN2 (0.56) | MMP2MMP13PGRMCL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | PHARMACIA CORPORATION | 2005-04-07 | — | — | US | disclosed |
| US-6794511-B2 | AN ENZYME INHIBITORS OF METALLOPROTEASE; TREATING CONNECTIVE TISSUE DEGRADATION CAUSED BY INFLAMMATION OR TUMOR | G. D. SEARLE | 2004-09-21 | — | — | US | disclosed |
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030191317-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO., (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1177173-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001085680-A2 | SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORPORATION (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000069819-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191317-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | MMP2 2/4885MMP13 5/4885MMP9 13/4885 |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | MMP2 2/4885MMP13 5/4885MMP9 13/4885 |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | ARSA, MMP1, MMP3 | MMP2 7/4885MMP13 8/4885MMP9 6/4885 |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | ARSA, AADAC, ASPH | MMP2 27/4885MMP13 26/4885MMP9 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.